TNFSF11 and Hypocalcemia: These include a higher incidence of hypocalcemia and rebound resorption post-cessation due to RANKL accumulation, as well as limited implant-site bioavailability that necessitates high systemic doses (Kumar et al., 2024; Fu et al., 2023).